SG11202100531RA - Novel thiazole derivatives and pharmaceutically acceptable salts thereof - Google Patents

Novel thiazole derivatives and pharmaceutically acceptable salts thereof

Info

Publication number
SG11202100531RA
SG11202100531RA SG11202100531RA SG11202100531RA SG11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA
Authority
SG
Singapore
Prior art keywords
pharmaceutically acceptable
acceptable salts
thiazole derivatives
novel thiazole
novel
Prior art date
Application number
SG11202100531RA
Other languages
English (en)
Inventor
Kwang Ok Lee
Jakyung Yoo
Jun Hee Lee
Mijung Lee
Kangwoo Lee
Jieun Min
Original Assignee
Yungjin Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yungjin Pharm Co Ltd filed Critical Yungjin Pharm Co Ltd
Publication of SG11202100531RA publication Critical patent/SG11202100531RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SG11202100531RA 2018-09-17 2019-09-11 Novel thiazole derivatives and pharmaceutically acceptable salts thereof SG11202100531RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180111001 2018-09-17
PCT/KR2019/011887 WO2020060112A1 (en) 2018-09-17 2019-09-11 Novel thiazole derivatives and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
SG11202100531RA true SG11202100531RA (en) 2021-02-25

Family

ID=69887568

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100531RA SG11202100531RA (en) 2018-09-17 2019-09-11 Novel thiazole derivatives and pharmaceutically acceptable salts thereof

Country Status (19)

Country Link
US (1) US20210284658A1 (pt)
EP (1) EP3853225B1 (pt)
JP (1) JP7235859B2 (pt)
KR (2) KR102130253B1 (pt)
CN (1) CN112739695A (pt)
AU (1) AU2019344240B2 (pt)
BR (1) BR112021004999A2 (pt)
CA (1) CA3106855A1 (pt)
CL (1) CL2021000594A1 (pt)
CO (1) CO2021003412A2 (pt)
EA (1) EA202190558A1 (pt)
IL (1) IL280639B (pt)
MX (1) MX2021002456A (pt)
PH (1) PH12021550572A1 (pt)
SG (1) SG11202100531RA (pt)
TW (1) TW202023548A (pt)
UA (1) UA125427C2 (pt)
WO (1) WO2020060112A1 (pt)
ZA (1) ZA202101652B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ATE288904T1 (de) 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
ATE345341T1 (de) * 2001-07-19 2006-12-15 Pfizer Italia Srl Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel
AU2005274390B2 (en) 2004-08-17 2012-01-19 F. Hoffmann-La Roche Ag Substituted hydantoins
US20090264415A2 (en) * 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2686756A1 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
MX2011004553A (es) * 2008-10-29 2011-07-20 Sirtris Pharmaceuticals Inc Piridina, piridina biciclica y analogos relacionados como moduladores de sirtuina.
US9221773B2 (en) * 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
US8952004B2 (en) * 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
AU2015240535A1 (en) 2014-04-04 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
MY190459A (en) 2015-06-04 2022-04-21 Aurigene Discovery Tech Ltd Substituted heterocyclyl derivatives as cdk inhibitors

Also Published As

Publication number Publication date
EP3853225A4 (en) 2022-06-15
WO2020060112A1 (en) 2020-03-26
KR20200032002A (ko) 2020-03-25
ZA202101652B (en) 2022-07-27
CA3106855A1 (en) 2020-03-26
EP3853225B1 (en) 2023-11-29
IL280639A (en) 2021-03-25
JP7235859B2 (ja) 2023-03-08
CN112739695A (zh) 2021-04-30
EA202190558A1 (ru) 2022-02-03
MX2021002456A (es) 2021-06-15
TW202023548A (zh) 2020-07-01
BR112021004999A2 (pt) 2021-06-08
CO2021003412A2 (es) 2021-04-08
IL280639B (en) 2022-07-01
JP2021535924A (ja) 2021-12-23
EP3853225C0 (en) 2023-11-29
AU2019344240B2 (en) 2022-09-29
US20210284658A1 (en) 2021-09-16
AU2019344240A1 (en) 2021-02-25
CL2021000594A1 (es) 2021-12-03
KR102130253B1 (ko) 2020-07-03
KR20200078465A (ko) 2020-07-01
UA125427C2 (uk) 2022-03-02
EP3853225A1 (en) 2021-07-28
PH12021550572A1 (en) 2021-10-25

Similar Documents

Publication Publication Date Title
IL278171A (en) Glucose-dependent insulin polypeptide and its uses
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
IL283486A (en) Thiazole derivatives kill microorganisms
IL283533A (en) Pentatein derivatives and their uses
EP3802495A4 (en) HETEROCYCLIC DERIVATIVES AND THEIR USE
SG11202010985TA (en) Heterocyclic derivatives and use thereof
PT3796975T (pt) Derivados de sulfonilaminobenzamida
IL279939A (en) History of thiadiazine
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
ZA202106024B (en) Heterocyclic derivatives
IL282527A (en) 5-Azaindazole history and their use
IL279441A (en) History of N-converted tetrahydrothinopyridines and their uses
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
IL282526A (en) 5-Azaindazole history and their use
ZA202101652B (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
EP3773597A4 (en) PHENOTHIAZINE DERIVATIVES AND THEIR USES
IL282142A (en) The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine
SI3778609T1 (sl) Derivati penama ali njenih soli, farmacevtski sestavki in njihova uporaba
EP3409662A4 (en) NOVEL CONNECTION AND PHARMACEUTICALLY COMPATIBLE SALT OF WHICH
ZA202008062B (en) Pharmaceutically acceptable salts of sepiapterin
IL279928A (en) History of heterocyclic sulfonamides and their pharmaceutical uses
EP3983415A4 (en) HETEROCYCLIC DERIVATIVES AND USE THEREOF
FIC20190056I1 (fi) talatsoparibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
HK1253072A1 (zh) 鬼臼毒素衍生物及其應用